Jon Bondebjerg
Profile
Jon Bondebjerg worked as a Chief Executive Officer at MycoTeQ A, an Attorney at Budde Schou A, a Project Manager at Combio A, and a Senior Research Scientist & Project Coordinator at Arpida AG from 2004 to 2007.
He holds a graduate degree from the University of Copenhagen and a doctorate degree from Danmarks Farmaceutiske Universitet.
Former positions of Jon Bondebjerg
Companies | Position | End |
---|---|---|
MycoTeQ A/S
MycoTeQ A/S Pharmaceuticals: MajorHealth Technology MycoTeQ is working to ease the discovery process for the pharmaceutical industry in order to ensure a steady flow of new chemical entities into the pipelines of this industry. The aspiration of MycoTeQ is to build a healthy business and become the world leading external provider of new chemical entities from micro fungi. In order to succeed on these ambitious targets MycoTeQ will adhere to the highest professional and scientific standards and seek to build strong and long-lasting relationships with its partners and customers. The company was founded in October 2006 and is headquartered in Copenhagen, Denmark. | President | 2012-04-01 |
Arpida AG
Arpida AG BiotechnologyHealth Technology Arpida AG develops and discovers drugs for microbial resistance. The company's products include intravenous iclaprim, and antibiotics. The antibiotics provides resistance towards the methicillin-resistant Staphylococcus aureus (MRSA). The company also discovers an oral formulation of iclaprim. The company was founded by Dr. Dieter Gillessen, Bernhard Erni and Dr. Ivan Kompis in July 1997 and is headquartered in Reinach, Switzerland. | Chief Tech/Sci/R&D Officer | 2006-12-31 |
Combio A/S | Corporate Officer/Principal | - |
Budde Schou A/S | General Counsel | - |
Training of Jon Bondebjerg
University of Copenhagen | Graduate Degree |
Danmarks Farmaceutiske Universitet | Doctorate Degree |
Experiences
Positions held
Linked companies
Private companies | 4 |
---|---|
Arpida AG
Arpida AG BiotechnologyHealth Technology Arpida AG develops and discovers drugs for microbial resistance. The company's products include intravenous iclaprim, and antibiotics. The antibiotics provides resistance towards the methicillin-resistant Staphylococcus aureus (MRSA). The company also discovers an oral formulation of iclaprim. The company was founded by Dr. Dieter Gillessen, Bernhard Erni and Dr. Ivan Kompis in July 1997 and is headquartered in Reinach, Switzerland. | Health Technology |
MycoTeQ A/S
MycoTeQ A/S Pharmaceuticals: MajorHealth Technology MycoTeQ is working to ease the discovery process for the pharmaceutical industry in order to ensure a steady flow of new chemical entities into the pipelines of this industry. The aspiration of MycoTeQ is to build a healthy business and become the world leading external provider of new chemical entities from micro fungi. In order to succeed on these ambitious targets MycoTeQ will adhere to the highest professional and scientific standards and seek to build strong and long-lasting relationships with its partners and customers. The company was founded in October 2006 and is headquartered in Copenhagen, Denmark. | Health Technology |
Budde Schou A/S | |
Combio A/S |
- Stock Market
- Insiders
- Jon Bondebjerg